Greenwich Lifesciences Inc (NASDAQ:GLSI) — Market Cap & Net Worth
Market Cap & Net Worth: Greenwich Lifesciences Inc (GLSI)
Greenwich Lifesciences Inc (NASDAQ:GLSI) has a market capitalization of $324.54 Million ($324.54 Million) as of June 19, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #14537 globally and #3402 in its home market, demonstrating a 7.92% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Greenwich Lifesciences Inc's stock price $23.99 by its total outstanding shares 14678208 (14.68 Million). Review debt load of Greenwich Lifesciences Inc to assess the company's total debt and financial obligations.
Greenwich Lifesciences Inc Market Cap History: 2020 to 2026
Greenwich Lifesciences Inc's market capitalization history from 2020 to 2026. Data shows growth from $535.31 Million to $352.13 Million (31.49% CAGR).
Index Memberships
Greenwich Lifesciences Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.42 Trillion | 0.01% | #386 of 976 |
|
NASDAQ Composite
IXIC
|
$40.74 Trillion | 0.00% | #1409 of 3165 |
Weight: Greenwich Lifesciences Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Greenwich Lifesciences Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Greenwich Lifesciences Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of GLSI by Market Capitalization
Companies near Greenwich Lifesciences Inc in the global market cap rankings as of June 19, 2026.
Key companies related to Greenwich Lifesciences Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #444 globally with a market cap of $62.63 Billion USD.
- UCB SA (BR:UCB): Ranked #549 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #573 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $458.99 |
| #444 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $62.63 Billion | $607.93 |
| #549 | UCB SA | BR:UCB | $49.68 Billion | €252.40 |
| #573 | Argen-X | BR:ARGX | $47.14 Billion | €780.20 |
Greenwich Lifesciences Inc Historical Marketcap From 2020 to 2026
Between 2020 and today, Greenwich Lifesciences Inc's market cap moved from $535.31 Million to $ 352.13 Million, with a yearly change of 31.49%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $352.13 Million | +14.18% |
| 2025 | $308.39 Million | +87.09% |
| 2024 | $164.84 Million | +6.75% |
| 2023 | $154.41 Million | -30.79% |
| 2022 | $223.11 Million | -37.53% |
| 2021 | $357.12 Million | -33.29% |
| 2020 | $535.31 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 18th, 2026 the market cap of Greenwich Lifesciences Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $324.54 Million USD |
| MoneyControl | $324.54 Million USD |
| MarketWatch | $324.54 Million USD |
| marketcap.company | $324.54 Million USD |
| Reuters | $324.54 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Greenwich Lifesciences Inc
Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States. Its lead product candidate is GP2, a HER2/neu transmembrane peptide, which is in Phase III clinical trial to prevent breast cancer recurrences in patients. The company also develops FLAMINGO-01, which is in Ph… Read more